<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222676</url>
  </required_header>
  <id_info>
    <org_study_id>ITA-MIL-IRCCS-INT-52/10</org_study_id>
    <secondary_id>CDR0000686602</secondary_id>
    <secondary_id>EUDRACT-2010-022653-41</secondary_id>
    <secondary_id>EU-21077</secondary_id>
    <nct_id>NCT01222676</nct_id>
  </id_info>
  <brief_title>Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder</brief_title>
  <official_title>A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.&#xD;
      Giving cisplatin and gemcitabine hydrochloride together with sorafenib tosylate may kill more&#xD;
      tumor cells. Giving them before surgery may make the tumor smaller and reduce the amount of&#xD;
      normal tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving cisplatin and gemcitabine&#xD;
      hydrochloride together with sorafenib tosylate works in treating patients with node-negative&#xD;
      transitional cell cancer of the bladder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the activity (pathological complete response) of neoadjuvant cisplatin and&#xD;
           gemcitabine hydrochloride in combination with sorafenib tosylate in patients with&#xD;
           muscle-invasive, node-negative transitional cell carcinoma of the bladder.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  To determine the potential biological correlates of disease response and drug activity&#xD;
           in tumor tissue samples before and after treatment.&#xD;
&#xD;
        -  To evaluate the correlation between fludeoxyglucose F 18 positron emission tomography&#xD;
           (18FDG-PET) and standard computed tomography (CT) results and the ability of changes of&#xD;
           18FDG-PET (as measured by EORTC criteria for response) to predict subsequent favorable&#xD;
           response to treatment (pathological complete response rate and progression-free&#xD;
           survival).&#xD;
&#xD;
      OUTLINE: Patients receive cisplatin IV over 20-30 minutes on day 1 and gemcitabine&#xD;
      hydrochloride IV over 30 minutes on days 1 and 8. Patients also receive sorafenib tosylate&#xD;
      twice daily on days 1-21. starting on day 1and continuing up to Treatment repeats every 21&#xD;
      days for 2 courses. Patients are reassessed after course 2, those who experience disease&#xD;
      progression or deemed unresectable are off study. Other patients continue the treatment for 2&#xD;
      more courses*.&#xD;
&#xD;
      NOTE: *Sorafenib tosylate are stopped 14 days prior to planned cystectomy.&#xD;
&#xD;
      No more than 30 days after completion of neoadjuvant therapy, patients undergo planned&#xD;
      radical cystectomy with pelvic lymph-node dissection off study.&#xD;
&#xD;
      Tumor tissue and serum samples may be collected during study for additional biological&#xD;
      studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological correlates of disease response and drug activity in tumor tissue samples before and after therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 18FDG-PET and standard CT results</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>imaging biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed transitional cell carcinoma (TCC) of the bladder at the time of diagnostic&#xD;
             transurethral resection of the bladder tumor (TURB)*&#xD;
&#xD;
               -  Muscle-invasive (T ≥ 2) disease at TURB OR clinical stage T3 or T4 disease (e.g.,&#xD;
                  T2 patients will not be eligible without a histological documentation of invasive&#xD;
                  disease)&#xD;
&#xD;
          -  NOTE: *Confirmation of TCC histology based on pathologic review at Fondazione Istituto&#xD;
             Nazionale dei Tumori Milan will be required in all cases.&#xD;
&#xD;
          -  Clinically node-negative (cN0) disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 2,000/µL&#xD;
&#xD;
          -  ANC ≥ 1,500/µL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT &lt; 2.5 times upper limit of normal (ULN) (&lt; 5 times ULN if due to hepatic&#xD;
             metastases)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Negative serology for the following infectious diseases:&#xD;
&#xD;
               -  HIV type 1 or 2&#xD;
&#xD;
               -  Hepatitis B surface antigen (active carriers)&#xD;
&#xD;
               -  Hepatitis C&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior systemic therapies except for intravesical therapy for superficial disease&#xD;
&#xD;
          -  No prior sorafenib tosylate&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Salvioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-2-2390-2359</phone>
      <email>roberto.salvioni@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

